Ascentage Pharma Stock Could More Than Double: Analyst
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
Stocks · News reference
Reported Earlier, Ascentage Pharma Wins China Breakthrough Therapy Designation For Bcl-2 Inhibitor Lisaftoclax Plus Acalabrutinib In Treatment-Naïve CLL/SLL
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Outperform rating.
Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46
Citigroup analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Buy rating and announces Price Target of $46.